Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | TUBB | P07437 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19358849 | 0.88 | TUBB (0.61) | MAPTLMNATP53MEN1POLB | |
| SCHEMBL19358841 | 0.83 | MEN1 (0.75) | MAPTLMNATP53ALDH1A1MEN1 | |
| SCHEMBL19358915 | 0.81 | CA1 (0.67) | MAPTLMNATP53ALDH1A1MEN1 | |
| SCHEMBL19358866 | 0.81 | MEN1 (0.60) | MAPTLMNATP53ALDH1A1USP2 | |
| SCHEMBL19358853 | 0.81 | TP53 (0.81) | MAPTLMNATP53ALDH1A1USP2 | |
| SCHEMBL5960116 | 0.79 | MEN1 (0.73) | MAPTLMNATP53ALDH1A1MEN1 | |
| SCHEMBL13744671 | 0.79 | HPGD (0.53) | TP53ALDH1A1MEN1POLBKMT2A | |
| SCHEMBL19358924 | 0.78 | MAPT (0.74) | MAPTLMNATP53ALDH1A1MEN1 | |
| SCHEMBL25547142 | 0.77 | CA12 (0.83) | LMNATP53ALDH1A1USP2MEN1 | |
| SCHEMBL19358850 | 0.77 | CA1 (0.72) | MAPTLMNATP53ALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3429588-B1 | AMIDE-SULFAMIDE DERIVATIVES, COMPOSITIONS, AND USES RELATED TO CXCR4 INHIBITION | UNIV EMORY (US) | 2024-09-18 | — | — | EP | disclosed |
| US-10669270-B2 | Amide-sulfamide derivatives, compositions, and uses related to CXCR4 inhibition | EMORY UNIVERSITY (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190084980-A1 | Amide-Sulfamide Derivatives, Compositions, and Uses Related to CXCR4 Inhibition | EMORY UNIVERSITY (US) | 2019-03-21 | — | — | US | disclosed |
| EP-3429588-A1 | AMIDE-SULFAMIDE DERIVATIVES, COMPOSITIONS, AND USES RELATED TO CXCR4 INHIBITION | Emory University (US) | 2019-01-23 | — | — | EP | disclosed |
| WO-2017160832-A1 | AMIDE-SULFAMIDE DERIVATIVES, COMPOSITIONS, AND USES RELATED TO CXCR4 INHIBITION | EMORY UNIVERSITY (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084980-A1 | Amide-Sulfamide Derivatives, Compositions, and Uses Related to CXCR4 Inhibition | CXCR4, CXCL12, CXCR2 | MAPT 4641/4885LMNA 4001/4885TP53 2641/4885 |
| US-10669270-B2 | Amide-sulfamide derivatives, compositions, and uses related to CXCR4 inhibition | CXCR4, CXCL12, CXCR2 | MAPT 4641/4885LMNA 4001/4885TP53 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.